Filing Flows › Aytu Biopharma (AYTU) › Q3 FY26
Aytu Biopharma (AYTU) Q3 FY26 earnings results (third quarter fiscal 2026)
10-Q filed May 13, 2026
Aytu Biopharma (AYTU) reported revenue of $12.4M for the third quarter fiscal 2026 (Q3 FY26), -33% from a year earlier and -18% from the quarter before. Operating margin was -32.7%, net loss $5.6M (45.3% of revenue).
Aytu Biopharma, Q3 FY26: revenue $12.4M (-33% year over year), operating margin -32.7%, net loss $5.6M, operating cash flow −$4.2M. The chart follows the revenue to costs, profit and cash.
| Q3 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $12.4M | -18% | -33% |
| Operating profit | −$4.1M | — | -268% |
| Net earnings | −$5.6M | — | -241% |
| Operating cash flow | −$4.2M | -214% | — |
What changed
Revenue was $12.4M in Q3 FY26, down 33% year over year and down 18% from the previous quarter.
Gross margin was 61.2%, down 8.2 points from Q3 FY25. Operating costs exceeded revenue by $4.1M, an operating margin of -32.7%. Operating expenses grew 12% against a revenue fall of 33%. The fastest-growing cost line was General & admin (+21%). The quarter ended with a net loss of $5.6M, narrower than the previous quarter's $10.6M loss.
Operating cash flow was −$4.2M. Non-cash charges added back $1.1M of depreciation and amortization and $148K of share-based compensation.
Questions
What was Aytu Biopharma's revenue in the third quarter fiscal 2026?
Aytu Biopharma (AYTU) reported revenue of $12.4M for the third quarter fiscal 2026 (Q3 FY26), -33% from a year earlier and -18% from the quarter before.
Was Aytu Biopharma profitable in the third quarter fiscal 2026?
Operating loss was $4.1M (-32.7% of revenue) and net loss $5.6M.
Source: Aytu Biopharma 10-Q on SEC EDGAR.